Overview
BBOT market data
Price History
BBOT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.30 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.44 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.00 – $14.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $743.4M · P/B 2.44.
Company News
JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25Benzinga · Aug 14, 2026, 4:16 PM
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) EstimateBenzinga · Aug 11, 2026, 8:39 PM
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On WednesdayBenzinga · Jul 8, 2026, 2:20 PM
8-K filing — BridgeBio Oncology Therapeutics, Inc. (BBOT)SEC EDGAR · Jun 22, 2026, 8:05 PM
Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22Benzinga · Jun 22, 2026, 5:35 PM